Related Experiment Video

Updated: Dec 27, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.8K

Development of microRNA-based therapy for pancreatic cancer

Andrew Fesler1, Jingfang Ju1

  • 1Department of Pathology, Stony Brook University, Stony Brook, NY.

Journal of Pancreatology
|March 6, 2020
PubMed

Insights

Pancreatic cancer (PDAC) treatment resistance necessitates new therapies. MicroRNAs (miRNAs) show promise as novel therapeutic agents to overcome chemoresistance and improve patient survival in pancreatic ductal adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death.
  • Therapeutic resistance significantly contributes to poor patient outcomes in PDAC.
  • Current treatment strategies face challenges due to complex chemoresistance mechanisms.

Purpose of the Study:

  • To review recent advancements in microRNA (miRNA) research concerning PDAC therapeutic resistance.
  • To explore the potential of miRNAs as novel therapeutic agents for PDAC.
  • To highlight the role of miRNAs in overcoming chemoresistance in pancreatic cancer.

Main Methods:

  • Comprehensive literature review of studies on miRNAs and PDAC chemoresistance.
  • Analysis of miRNA roles in regulating resistance pathways.
  • Evaluation of miRNA-based therapeutic strategies.

Main Results:

  • miRNAs play multifaceted roles in PDAC chemoresistance.
  • miRNAs exhibit multitargeted functions, making them suitable for complex resistance mechanisms.
  • Emerging evidence supports the potential of miRNAs as therapeutic agents.

Conclusions:

  • miRNAs represent a promising avenue for novel therapeutic approaches in PDAC.
  • Targeting miRNAs could help overcome therapeutic resistance in pancreatic cancer.
  • Further research into miRNA-based therapies is crucial for improving PDAC patient outcomes.
Keywords:
ChemotherapyGemcitabinePancreatic ductal adenocarcinomaResistancemiRNA

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

259
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K